Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MLYCD | O95822 | 2/20 | 0.35 |
| ▸ | QDPR | P09417 | 1/20 | 0.33 |
| ▸ | USP7 | Q93009 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
| ▸ | PLG | P00747 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17203791 | 0.83 | — | — | |
| SCHEMBL4660454 | 0.82 | MLYCD (0.35) | MLYCD | |
| SCHEMBL14314254 | 0.81 | ALOX15 (0.39) | ALOX15MLYCDQDPRKDM4ESMN1; SMN2 | |
| SCHEMBL20298979 | 0.80 | WDR5 (0.39) | TDP1MLYCDKDM4ESMN1; SMN2 | |
| SCHEMBL20298764 | 0.80 | WDR5 (0.36) | MLYCDSMN1; SMN2MKNK1 | |
| SCHEMBL20789235 | 0.79 | FPR3 (0.38) | MLYCD | |
| SCHEMBL20789238 | 0.79 | FPR3 (0.38) | MLYCD | |
| SCHEMBL21122190 | 0.79 | ESR2 (0.32) | — | |
| SCHEMBL21139263 | 0.79 | ESR2 (0.32) | — | |
| SCHEMBL20807215 | 0.78 | WDR5 (0.39) | TDP1KDM4EGAASMN1; SMN2MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024253416-A1 | PYRIMIDINE/PYRIDINE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2024-12-12 | — | — | WO | disclosed |
| CN-117279896-A | Amino substituted pyrido ring compounds, preparation method and application thereof | 劲方医药科技(上海)有限公司 | 2023-12-22 | — | — | CN | disclosed |
| WO-2022214044-A1 | AMINE-SUBSTITUTED PYRIDINE FUSED RING COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2022-10-13 | — | — | WO | disclosed |
| US-20110136789-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136789-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | TDP1 3773/4885ALOX15 4406/4885MLYCD 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.